Health care stocks were flat to higher premarket Tuesday with the Health Care Select Sector SPDR Fund (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) recently inactive.
Novo Nordisk's (NVO) weight-loss drug Wegovy is being offered in smaller doses of a compounded version by online weight-loss tool Noom, Reuters reported, citing senior company officials. Shares of Novo Nordisk were over 3% higher pre-bell.
NeurAxis (NRXS) shares surged past 160% after the company said the US Food and Drug Administration granted clearance to expand the use of its IB-Stim device for treating functional abdominal pain linked to functional dyspepsia and nausea in patients aged 8 to 21.
Zymeworks (ZYME) shares were up over 1% after the company said new preclinical data on its experimental respiratory inflammation drug ZW1528 has shown positive results.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。